734% Profit Growth: Pharma Stock hits 10% upper circuit after announcing strong Q3 results

Synopsis: Syschem (India) Limited reports 81.97% YoY revenue growth and a 734% YoY net profit surge in Q3 FY26 results.

This Pharma Stock, engaged in manufacturing active pharmaceutical ingredients (APIs), bulk drugs, intermediates, and speciality chemicals for the pharmaceutical industry, hit a 10 percent upper circuit after the company reported December quarterly results with a 734 percent YoY increase in net profit.

With a market capitalization of Rs. 231.71 crores, the shares of Syschem (India) Limited hit a 10 percent upper circuit of Rs. 54.52 per share on Tuesday, up from its previous closing price of Rs. 49.57 per share. Since then, the stock has retreated and is currently trading at Rs. 53.25 per equity share. 

Q3 FY26 Result

Coming into the quarterly results of Syschem (India) Limited, the company’s consolidated revenue from operations increased by 81.97 percent YOY, from Rs. 77.76 crore in Q3 FY25 to Rs. 141.50 crore in Q3 FY26, and grew by 36.58 percent QoQ from Rs. 103.60 crore in Q2 FY26.

In Q3 FY26, Syschem (India) Limited’s consolidated net profit increased by 734 percent YOY, reaching Rs. 4.17 crore compared to Rs. 0.50 crore during the same period last year. As compared to Q2 FY26, the net profit has increased by 119.47 percent, from Rs. 1.90 crore.

The basic earnings per share increased by 638.46 percent and stood at Rs. 0.96 as against Rs. 0.13 recorded in the same quarter in the previous year, FY2025. Syschem (India) Limited’s revenue has grown at a CAGR of 77.87 percent over the last five years.

In terms of return ratios, the company’s ROCE and ROE stand at 1.47 percent and 0.62 percent, respectively. Syschem (India) Limited has an earnings per share (EPS) of Rs. 1.88, and it’s a debt-free company

Current Capacity

Syschem (India) Limited has established a strong operational foundation with an installed production capacity of approximately 4,200 TPA across a 6-acre land bank, enabling scalable infrastructure and future-ready expansion. The company is actively enhancing and expanding its facilities with a targeted capacity of 8,000 TPA, reflecting its long-term growth strategy. 

Syschem serves over 100 consumers and traders globally, supported by a portfolio of more than 7 API SKUs and a growing international presence spanning 3 continents and more than 10 countries.

Syschem (India) Limited was established in 1993 and is based in Chandigarh. The company specialises in the manufacturing of active pharmaceutical ingredients (APIs), bulk drugs, intermediates, and speciality chemicals. 

The company focuses on the beta-lactam group of APIs alongside contract manufacturing services for the pharmaceutical industry. The company produces a diverse range of high-quality APIs, serving pharmaceutical clients with products from speciality drugs to essential intermediates. 

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post 734% Profit Growth: Pharma Stock hits 10% upper circuit after announcing strong Q3 results appeared first on Trade Brains.